Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: A 28-day, open-label study

Clinical Therapeutics

Volumn 30, Issue 9, 2008, Pages 1658-1666

  Mathew, Sanjay J ^a   Garakani, Amir ^a   Reinhard, Jr, John F ^b   Oshana, Scott ^c   Donahue, Stephen ^d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Epix Pharmaceuticals   (United States)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

^d Ore Pharmaceuticals Inc   (United States)

Author keywords

5 HT1A; buspirone; clinical trial; GAD; generalized anxiety disorder; nonazapirone; PRX 00023; serotonin; serotonin 1A

Indexed keywords

BUSPIRONE; N [3 [4 [4 (CYCLOHEXYLMETHYLSULFONAMIDO)BUTYL] 1 PIPERAZINYL]PHENYL]ACETAMIDE; PLACEBO; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR;

ADULT; ARTICLE; ATAXIA; BACKACHE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FLU LIKE SYNDROME; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HEADACHE; HUMAN; MALE; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; OUTPATIENT CARE; PATHOPHYSIOLOGY; PROTEIN FUNCTION; RATING SCALE; REMISSION; RESTLESSNESS; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN AGONISTS; SINGLE-BLIND METHOD; SULFONAMIDES; TREATMENT OUTCOME;

EID: 53049109786     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.09.006     Document Type: Article

References (33)

1. Fricchione G. Clinical practice. Generalized anxiety disorder. N Engl J Med 351 (2004) 675-682
2. Mathew SJ, Hoffman E, Pharmacotherapy for Generalized Anxiety Disorder. New York, NY: Oxford University Press. In press.
3. Alpert J.E., Franznick D.A., Hollander S.B., and Fava M. Gepirone extended-release treatment of anxious depression: Evidence from a retrospective subgroup analysis in patients with major depressive disorder. J Clin Psychiatry 65 (2004) 1069-1075
4. Keller M.B., Ruwe F.J., Janssens C.J., et al. Relapse prevention with gepirone ER in outpatients with major depression. J Clin Psychopharmacol. 25 (2005) 79-84
5. Rickels K., Schweizer E., DeMartinis N., et al. Gepirone and diazepam in generalized anxiety disorder: A placebo-controlled trial. J Clin Psychopharmacol 17 (1997) 272-277
6. Ninan P.T., and Muntasser S. Buspirone, Gepirone. Chapter XXX. In: Schatzberg A.F., and Nemeroff C.B. (Eds). The American Psychiatric Publishing Textbook of Psychopharmacology. 3rd ed. (2004), American Psychiatric Publishing, Washington, DC 391-404
7. Chessick C.A., Allen M.H., Thase M.E., et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev. 3 (2006) CD006115
8. Pollack M.H., Roy-Byrne P.P., Van Ameringen M., et al. The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: Results of a placebocontrolled study. J Clin Psychiatry 66 (2005) 1401-1408
9. Ramboz S., Oosting R., Amara D.A., et al. Serotonin receptor 1A knockout: An animal model of anxietyrelated disorder. Proc Natl Acad Sci U S A 95 (1998) 14476-14481
10. Zhuang X., Gross C., Santarelli L., et al. Altered emotional states in knockout mice lacking 5-HT1A or 5-HT1B receptors. Neuropsychopharmacology 21 Suppl 2 (1999) 52S-60S
11. Mayorga A.J., Dalvi A., Page M.E., et al. Antidepressant-like behavioral effects in 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) receptor mutant mice. J Pharmacol Exp Ther 298 (2001) 1101-1107
12. Santarelli L., Saxe M., Gross C., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301 (2003) 805-809
13. Pecknold J.C., Luthe L., Scott-Fleury M.H., and Jenkins S. Gepirone and the treatment of panic disorder: An open study. J Clin Psychopharmacol 13 (1993) 145-149
14. Blier P., and de Montigny C. Electrophysiological investigation of the adaptive response of the 5-HT system to the administration of 5-HT1A receptor agonists. J Cardiovasc Pharmacol 15 Suppl 7 (1990) S42-S48
15. Maron E., and Shlik J. Serotonin function in panic disorder: Important, but why?. Neuropsychopharmacology 31 (2006) 1-11
16. Masand P.S., and Gupta S. The safety of SSRIs in generalised anxiety disorder: Any reason to be anxious?. Expert Opin Drug Saf. 2 (2003) 485-493
17. Pourmotabbed T., Mcleod D.R., Hoehn-Saric R., et al. Treatment, discontinuation, and psychomotor effects of diazepam in women with generalized anxiety disorder. J Clin Psychopharmacol 16 (1996) 202-207
18. Busto U., Sellers E.M., Naranjo C.A., et al. Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med 315 (1986) 854-859
19. Landén M., Eriksson E., Agren H., and Fahlén T. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol 19 (1999) 268-271
20. Rickels K., Amsterdam J.D., Clary C., et al. Buspirone in major depression: A controlled study. J Clin Psychiatry 52 (1991) 34-38
21. Rickels K., Derivan A., Kunz N., et al. Zalospirone in major depression: A placebo-controlled multicenter study. J Clin Psychopharmacol 16 (1996) 212-217
22. Becker O.M., Dhanoa D.S., Marantz Y., et al. An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression. J Med Chem 49 (2006) 3116-3135
23. Iyer G.R., Reinhard Jr. J.F., Oshana S., et al. Tolerability, pharmacokinetics, and neuroendocrine effects of PRX00023, a novel 5-HT1A agonist, in healthy subjects. J Clin Pharmacol 47 (2007) 817-824
24. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) (1994), APA, Washington, DC
25. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 32 (1959) 50-55
26. Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised (DHEW Publication No. ADM 76338) (1976), US Government Printing Office, Washington, DC
27. Zigmond A.S., and Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr Scand 67 (1983) 361-370
28. Rickels K., Schweizer E., Case W.G., and Greenblatt D.J. Long term therapeutic use of benzodiazepines, I. Effects of abrupt discontinuation. [published correction appears in Arch Gen Psychiatry. 1991;48:51]. Arch Gen Psychiatry 47 (1990) 899-907
29. Cutler N.R., Sramek J.J., Keppel Hesselink J.M., et al. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: A prospective multicenter trial. J Clin Psychopharmacol 13 (1993) 429-437
30. US Food and Drug Administration, Medical Dictionary for Regulatory Activities [MedDRA Web site]. http://www.meddramsso.com/MSSOWeb/index.htm. Accessed January 15, 2005.
31. Shapiro S.S., and Wilk M.B. An analysis of variance test for normality (complete samples). Biometrika 52 (1965) 591-611
32. Massey Jr. F.J. The Kolmogorov- Smirnov test for goodness of fit. J Am Stat Assoc 46 (1951) 68-77
33. Martin P. 1-(2-Pyrimidinyl)-piperazine may alter the effects of the 5-HT1A agonist in the learned helplessness paradigm in rats. Psychopharmacology (Berl) 104 (1991) 275-278